Follow us on:

Linkedin Facebook

hVIVO to publish FY results on 9 April 2024

hVIVO
[shareaholic app="share_buttons" id_name="post_below_content"]

hVIVO plc (LON:HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it will release its full year results for the twelve months ended 31 December 2023 on Tuesday 9 April 2024.

Analyst briefing

A briefing open to equity research analysts will take place on Tuesday 9 April 2024 at 12.00 pm BST. To register and for more details please contact Walbrook PR on [email protected].

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

Latest Company News

hVIVO plc

hVIVO publishes breakthrough COVID-19 biomarker study in Nature Communications

hVIVO plc announces a breakthrough in identifying biomarkers for respiratory infections, published in Nature Communications, advancing diagnostics and patient care.
hVIVO

hVIVO signs £11.5m contract for antiviral RSV study with global pharma client

hVIVO plc, a leader in human challenge trials, secures an £11.5M contract with a global pharma client to test an antiviral using its RSV model.
hVIVO plc

hVIVO CEO Yamin ‘Mo’ Khan presenting in-person at the Jefferies Healthcare Conference

hVIVO

hVIVO reports positive results from RSV antiviral human challenge trial

hVIVO plc, a leader in human challenge trials, announces positive results for Enanta Pharmaceuticals' RSV antiviral candidate EDP-323 in a recent study.
hVIVO

hVIVO officially launches full suite of its hLAB service offering

Open Orphan

hVIVO reports strong first half, delivering record revenues and margins

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.